Abbvie 2Q Revenues: $10.4 billion (+26%) 2Q Loss: $739 million (earnings were $741 million 2Q19) YTD Revenues: $14.7 billion (+52%) YTD Earnings: $2.3 billion (-29%) Comments: Revenues from the Immunology portfolio were $5.3 billion, up 8%. U.S. Humira sales were nearly $4 billion, up 5%; International Humira sales were $863 million, down 20% due to biosimilar competition. Skyrizi sales were $330 million. Rinvoq revenues were $149 million. Revenues from the Hematologic Oncolo...